Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evolutionary resistance of metastatic breast cancer

ABSTRACT: Evolutionary resistance of metastatic breast cancer

PROVIDER: PRJNA814379 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Evolutionary resistance of metastatic breast cancer

Project description:Evolutionary resistance of metastatic breast cancer

| PRJNA814378 | ENA

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

Project description:Estrogen receptor positive (ER+) breast cancers that develop resistance to therapies that target the ER are the most common cause of breast cancer death. Beyond mutations in ER, which occur in 25-30% of patients treated with aromatase inhibitors (AIs), our understanding of clinical mechanisms of resistance to ER-directed therapies remains incomplete. We identified activating HER2 mutations in metastatic biopsies from eight patients with ER+ metastatic breast cancer who had developed resistance to ER-directed agents, including AIs, tamoxifen, and fulvestrant. Examination of treatment-naïve primary tumors in five patients revealed no evidence of pre-existing mutations in four of five patients, suggesting that these mutations were acquired under the selective pressure of ER-directed therapy. These mutations were mutually exclusive with ER mutations, suggesting a distinct mechanism of acquired resistance to ER-directed therapies. In vitro analysis confirmed that these mutations conferred estrogen independence. In addition, and in contrast to ER mutations, these mutations resulted in resistance to tamoxifen, fulvestrant, and the CDK4/6 inhibitor palbociclib. Resistance was overcome by combining ER-directed therapy with the irreversible HER2 kinase inhibitor neratinib, highlighting an effective treatment strategy in these patients.

2018-10-19 | GSE121411 | GEO

Metastatic immunoediting in breast cancer cells

Project description:Metastatic immunoediting in breast cancer cells

| PRJNA1081861 | ENA

PBMCs from metastatic breast cancer patients

Project description:PBMCs from metastatic breast cancer patients

| PRJNA730015 | ENA

Response and Resistance to ER-directed Therapy in ER+ Metastatic Breast Cancer

Project description:Response and Resistance to ER-directed Therapy in ER+ Metastatic Breast Cancer

| PRJNA369715 | ENA

Differential analysis of nucleolar proteomics in metastatic breast cancer

Project description:The nucleolus, responsible for ribosome biogenesis, acts as a key center for detecting and responding to cellular stress. Additionally, growing evidence suggests that ribosome biogenesis may play a significant role in promoting metastasis. A proteomic screen of nucleolar protein content between metastatic and non-metastatic breast cancers found that metastatic breast cancer cell lines have a unique nucleolar proteome signature as compared to non-metastatic breast cancer cell lines.

2025-07-27 | PXD060687 | Pride

Establishment of palbociclib resistant metastatic breast cancer patient-derived xenograft models

Project description:Identify therapeutic vulnerabilities of palbociclib resistance in metastatic breast cancer patient-derived xenograft models and identify key biomarkers that correlate with development of resistance to inform new treatment directions

2023-07-10 | GSE229235 | GEO

Aurora US Metastatic Breast Cancer Retrospective Project

Project description:Aurora US Metastatic Breast Cancer Retrospective Project

| PRJNA767028 | ENA

Aurora US Metastatic Breast Cancer Retrospective Project

Project description:Aurora US Metastatic Breast Cancer Retrospective Project

| PRJNA767029 | ENA

Maintenance of epithelial traits and resistance to mesenchymal reprogramming promote proliferation in metastatic breast cancer

Project description:Despite important advances in the treatment of breast cancer, the 5-year survival rate for patients with distant metastasis remains less than 30%. Metastasis is a complex, multi-step process beginning with local invasion and ending with the outgrowth of systemically disseminated cells into actively proliferating metastases that ultimately cause the destruction of vital organs. It is this last step that limits patient survival and, at the same time, remains the least understood mechanistically. Here, we focus on understanding determinants of metastatic outgrowth using metastatic effusion biopsies from stage IV breast cancer patients. By modelling metastatic outgrowth through xenograft transplantation, we show that tumour initiation potential of patient-derived metastatic breast cancer cells across breast cancer subtypes is strongly linked to high levels of EPCAM expression. Breast cancer cells with high EPCAM levels are highly plastic and, upon induction of epithelial-mesenchymal transition (EMT), readily adopt mesenchymal traits while maintaining epithelial identity. In contrast, low EPCAM levels are caused by the irreversible reprogramming to a mesenchymal state with concomitant suppression of metastatic outgrowth. The ability of breast cancer cells to retain epithelial traits is tied to a global epigenetic program that limits the actions of EMT-transcription factor ZEB1, a suppressor of epithelial genes. Our results provide direct evidence that maintenance of epithelial identity is required for metastatic outgrowth while concomitant expression of mesenchymal markers enables plasticity. In contrast, loss of epithelial traits is characteristic of an irreversible mesenchymal reprogramming associated to a deficiency for metastatic outgrowth. Collectively, our data provide a framework for the intricate intercalation of mesenchymal and epithelial traits in metastatic growth.

2023-04-30 | GSE138329 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data